Skip to main content
Erschienen in:

21.12.2018 | review

Toxicities in B‑cell non-Hodgkin lymphoma—new agents, new pitfalls

verfasst von: Thomas Spanberger, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Summary

Immunochemotherapy has long been the backbone of all treatment for B‑cell non-Hodgkin lymphoma. These therapies led to long-term disease control or even cure for some patients. However, these treatments also caused—sometimes severe—toxicities and deterioration of the quality of life. Novel agents targeting the B‑cell-receptor pathway and bcl2 have made great inroads in the treatment of mature lymphoid neoplasms. These new agents present themselves with a wide variety of new toxicities, which have to be taken into account when being administered to our patients. Hematological toxicities are very common. All new agents lead to various levels of immune suppression or immune modulation, which is often not easily quantifiable. Opportunistic infections such as progressive multifocal leukoencephalopathy, pneumocystis pneumonia, other mycotic infections, cytomegalovirus infections and pneumocystis pneumonia have been described, sometimes with fatal outcome. Ibrutinib shows increased risk of atrial fibrillation. It also increases the risk of bleeding, making the proper anticoagulatory management of patients developing atrial fibrillation under treatment a challenge. Idelalisib causes severe, sometimes fatal immune-mediated end-organ toxicities, especially colitis, pneumonitis, and transaminitis. Copanlisib leads to metabolic changes, namely episodes of hyperglycemia and arterial hypertension. Venetoclax has caused clinically significant tumor lysis syndrome. The introduction of a prolonged ramp-up phase of step wise dose escalation has decreased the rate of clinically significant tumor lysis syndrome. The drug also causes high rates of hematological toxicities, especially neutropenia.
Literatur
1.
Zurück zum Zitat Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER cancer statistics review, 1975-2015. Bethesda: National Cancer Institute; 2018. based on November 2017 SEER data submission, posted to the SEER web site. https://seer.cancer.gov/csr/1975_2015. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER cancer statistics review, 1975-2015. Bethesda: National Cancer Institute; 2018. based on November 2017 SEER data submission, posted to the SEER web site. https://​seer.​cancer.​gov/​csr/​1975_​2015.
2.
Zurück zum Zitat Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B‑cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–v25.CrossRef Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B‑cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–v25.CrossRef
4.
Zurück zum Zitat Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.CrossRef Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.CrossRef
6.
Zurück zum Zitat Raisch DW, Rafi JA, Chen C, Bennett CL. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA’s adverse event reporting system. Expert Opin Drug Saf. 2016;15(8):1003–11.CrossRef Raisch DW, Rafi JA, Chen C, Bennett CL. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA’s adverse event reporting system. Expert Opin Drug Saf. 2016;15(8):1003–11.CrossRef
7.
Zurück zum Zitat Reinwald M, Silva JT, Mueller NJ, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect. 2018;24(Suppl 2):S53–S70.CrossRef Reinwald M, Silva JT, Mueller NJ, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect. 2018;24(Suppl 2):S53–S70.CrossRef
8.
Zurück zum Zitat Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–506.CrossRef Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–506.CrossRef
9.
Zurück zum Zitat Rhodes J, Mato A, Sharman JP. Monitoring and management of toxicities of novel B cell signaling agents. Curr Oncol Rep. 2018;20(6):49.CrossRef Rhodes J, Mato A, Sharman JP. Monitoring and management of toxicities of novel B cell signaling agents. Curr Oncol Rep. 2018;20(6):49.CrossRef
10.
Zurück zum Zitat Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM, Sweetenham JW. Proposed algorithm for managing Ibrutinib-related atrial fibrillation. Oncology (Williston Park, NY). 2016;30(11):970–4–980–1, C3. Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM, Sweetenham JW. Proposed algorithm for managing Ibrutinib-related atrial fibrillation. Oncology (Williston Park, NY). 2016;30(11):970–4–980–1, C3.
11.
Zurück zum Zitat Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23.CrossRef Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23.CrossRef
12.
Zurück zum Zitat Jaglowski SM, Jones JA, Nagar V, et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015;126(7):842–50.CrossRef Jaglowski SM, Jones JA, Nagar V, et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015;126(7):842–50.CrossRef
13.
Zurück zum Zitat Caron F, Leong DP, Hillis C, Fraser G, Siegal D. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Adv. 2017;1(12):772–8.CrossRef Caron F, Leong DP, Hillis C, Fraser G, Siegal D. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Adv. 2017;1(12):772–8.CrossRef
15.
Zurück zum Zitat Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–18.CrossRef Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–18.CrossRef
16.
Zurück zum Zitat Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.CrossRef Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.CrossRef
17.
Zurück zum Zitat Sehn LH, Hallek M, Jurczak W, Brown JR, Barr PM, Catalano J, Coutre SE, Furman RR, Lamanna N, Loïc Y, Zelenetz AD, Sharman JP, DeVos S, Adewoye AH, Yeonhee K, Flinn IW, Salles GA. A retrospective analysis of pneumocystis Jirovecii pneumonia infection in patients receiving Idelalisib in clinical trials. Blood. 2018;128(22):3705. http://www.bloodjournal.org/content/128/22/3705. Sehn LH, Hallek M, Jurczak W, Brown JR, Barr PM, Catalano J, Coutre SE, Furman RR, Lamanna N, Loïc Y, Zelenetz AD, Sharman JP, DeVos S, Adewoye AH, Yeonhee K, Flinn IW, Salles GA. A retrospective analysis of pneumocystis Jirovecii pneumonia infection in patients receiving Idelalisib in clinical trials. Blood. 2018;128(22):3705. http://​www.​bloodjournal.​org/​content/​128/​22/​3705.
18.
Zurück zum Zitat Greenwell IB, Ip A, Cohen JB. PI3K inhibitors: understanding toxicity mechanisms and management. Oncology (Williston Park, NY). 2017;31(11):821–8. Greenwell IB, Ip A, Cohen JB. PI3K inhibitors: understanding toxicity mechanisms and management. Oncology (Williston Park, NY). 2017;31(11):821–8.
19.
Zurück zum Zitat Coutré SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56(10):2779–86.CrossRef Coutré SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56(10):2779–86.CrossRef
20.
Zurück zum Zitat Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3‑kinase inhibition by Copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898–905.CrossRef Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3‑kinase inhibition by Copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898–905.CrossRef
21.
Zurück zum Zitat Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–78.CrossRef Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–78.CrossRef
22.
Zurück zum Zitat Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of Venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–33.CrossRef Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of Venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–33.CrossRef
23.
Zurück zum Zitat Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-Rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–20.CrossRef Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-Rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–20.CrossRef
24.
Zurück zum Zitat Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–22.CrossRef Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–22.CrossRef
25.
Zurück zum Zitat Coiffier B, Altman A, Pui C‑H, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16):2767–78.CrossRef Coiffier B, Altman A, Pui C‑H, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16):2767–78.CrossRef
Metadaten
Titel
Toxicities in B‑cell non-Hodgkin lymphoma—new agents, new pitfalls
verfasst von
Thomas Spanberger, MD
Publikationsdatum
21.12.2018
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-018-0466-1

Weitere Artikel der Ausgabe 1/2019

memo - Magazine of European Medical Oncology 1/2019 Zur Ausgabe